文献速递衰弱、肌少症与跌倒老年综合评估认知障碍与谵妄

50岁及以上乳腺癌患者衰弱与认知的纵向关系

Longitudinal Relationship Between Frailty and Cognition in Patients 50 Years and Older with Breast Cancer.
PubMed 文献 · J Am Geriatr Soc · 2019-01-01

该研究对376例接受化疗的50岁及以上乳腺癌患者和234例无癌症年龄匹配对照进行纵向观察,发现患者基线衰弱评分更高、自报认知更差,且自报认知及客观注意记忆测试的纵向下降与衰弱增加相关,提示两者均需评估。

要点

  • 乳腺癌患者化疗前衰弱评分高于对照,自报认知评分低于对照。
  • 自报认知下降与衰弱增加在化疗期间及化疗后6个月相关。
  • 客观注意和记忆测试下降也与衰弱增加相关,65岁以上亚组仍显著。

核心结论

  • 50岁及以上乳腺癌患者自报认知和客观注意记忆的纵向下降与衰弱增加相关,认知和衰弱均为重要评估因素。

研究设计与样本

  • 前瞻性纵向观察研究的二次分析,纳入376例接受辅助/新辅助化疗的50岁及以上乳腺癌患者和234例年龄匹配无癌症对照。
  • 在化疗前、化疗后及化疗后6个月三个时间点测量衰弱和认知,采用线性回归模型调整协变量。

主要发现

  • 客观认知测量在基线时无统计学差异。
  • 癌症患者FACT-Cog在化疗前至化疗后(P < .05)及化疗前至化疗后6个月(P < .01)的下降与衰弱评分增加相关。
  • 癌症患者控制性口语词语联想测试(P < .05)和连线测试(P < .01)在化疗前至化疗后的恶化与衰弱增加相关;延迟匹配样本测试在化疗前至化疗后6个月的下降与衰弱增加相关(P < .05)。
  • 65岁及以上亚组分析中上述关联仍显著。

临床怎么用

  • 对50岁及以上接受化疗的乳腺癌患者,应同时评估衰弱和认知功能。
  • 化疗期间及化疗后6个月内认知下降可能提示衰弱增加,需动态监测。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate relationships between frailty and cognition longitudinally in adults 50 years and older with breast cancer receiving chemotherapy. DESIGN: Secondary analysis of a prospective longitudinal observational study. SETTING: University of Rochester NCI Community Oncology Research Program community oncology clinics. PARTICIPANTS: Patients with breast cancer age 50 and older receiving adjuvant/neoadjuvant chemotherapy (n = 376) and age-matched controls without cancer (n = 234). MEASUREMENTS: Frailty was assessed using a modified frailty score from self-reported assessments (weakness, exhaustion, physical activity, and gait speed). Cognition was assessed by patient report (Functional Assessment of Cancer Therapy-Cognition [FACT-Cog]) and objective measures. Frailty and cognition were measured at three time points (prechemotherapy [A1], postchemotherapy [A2], and 6 months postchemotherapy [A3]; similar time interval for controls). Linear regression models evaluated associations between frailty and cognition adjusting for covariates. RESULTS: The average age was 59 years (standard deviation = 6.4 y). At baseline, patients with cancer had a higher mean frailty score (1.21 vs .73; P < .001) and lower mean FACT-Cog score (158.4 vs 167.3; P < .001) compared with controls. Objective cognitive measures were not statistically different. Longitudinal decline in FACT-Cog between A1 and A2 (P < .05) and between A1 and A3 (P < .01) was associated with increased frailty score in patients compared with controls. Longitudinal worsening in Controlled Oral Word Association (P < .05) and Trail-Making Test (P < .01) were associated with an increase in frailty between A1 and A2 in patients compared with controls; longitudinal decline in the Delayed Match to Sample test was associated with an increase in frailty between A1 and A3 (P < .05) in patients compared with controls. This finding remained significant for a subset analysis of those aged 65 and older. CONCLUSION: In patients with breast cancer aged 50 and older, longitudinal decline in FACT-Cog and objective measures of attention and memory were associated with increased frailty during treatment and up to 6 months posttreatment. Overall, our study suggests cognition and frailty are both important factors to assess in breast cancer patients. J Am Geriatr Soc 67:928-936, 2019.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Magnuson A, Lei L, Gilmore N, et al. Longitudinal Relationship Between Frailty and Cognition in Patients 50 Years and Older with Breast Cancer. J Am Geriatr Soc. 2019. PMID: 31034595. doi:10.1111/jgs.15934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。